Header Logo

Connection

David Guertin to Sirolimus

This is a "connection" page, showing publications David Guertin has written about Sirolimus.
Connection Strength

0.596
  1. Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol Med. 2005 Aug; 11(8):353-61.
    View in: PubMed
    Score: 0.245
  2. Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM, Davis JG, Salmon AB, Richardson A, Ahima RS, Guertin DA, Sabatini DM, Baur JA. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science. 2012 Mar 30; 335(6076):1638-43.
    View in: PubMed
    Score: 0.097
  3. Li H, Cotton JL, Guertin DA. Evaluating the therapeutic potential of mTOR inhibitors using mouse genetics. Methods Mol Biol. 2012; 821:329-47.
    View in: PubMed
    Score: 0.095
  4. Guertin DA, Sabatini DM. The pharmacology of mTOR inhibition. Sci Signal. 2009 Apr 21; 2(67):pe24.
    View in: PubMed
    Score: 0.079
  5. Guertin DA, Guntur KV, Bell GW, Thoreen CC, Sabatini DM. Functional genomics identifies TOR-regulated genes that control growth and division. Curr Biol. 2006 May 23; 16(10):958-70.
    View in: PubMed
    Score: 0.065
  6. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004 Jul 27; 14(14):1296-302.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.